期刊文献+

结直肠癌靶向治疗的研究进展

下载PDF
导出
摘要 尽管化学药物治疗在结直肠癌方面取得了比较好的效果,但由于肿瘤细胞的耐药性和药物的毒副作用往往使得很多中晚期的肿瘤患者失去了治疗的机会。近年来靶向治疗的进展给结直肠癌的患者带来了希望。通过对肿瘤生长的关键通路如:表皮生长因子通路、新生血管形成通路等采用小分子化合物阻断其关键酶或采用单克隆抗体与其特异的生长因子或其受体竟争性结合等方式,选择性的阻断肿瘤细胞的生长,取得了非常好的临床效果,尤其是与化疗药物的合用常常可以取得叠加的效果。
机构地区 上海
出处 《中国药物应用与监测》 CAS 2007年第6期6-9,共4页 Chinese Journal of Drug Application and Monitoring
  • 相关文献

参考文献15

  • 1[3]Saltz L.Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor[J].J Clin Oncol,2004,22(6):1.
  • 2[4]Tabernero JM,Custem EV,Sastre J,et al.An international phase Ⅱ study of cetuximab in combination with oxaliplatin/5-fluorouracil(5-FU)/folinic acid(FA)(FOLFOX4) in the firstline treatment of patients with metastatic colorectal cancer (MCRC)expressing Epidemal Growth Factor Receptor (EGFR).Preliminary results[J].Proc Am Soc Oncol,2004,23:A3512.
  • 3冯丹,王雅杰.EGFR家族靶向肿瘤治疗研究进展[J].国际肿瘤学杂志,2006,33(1):11-14. 被引量:5
  • 4[6]Foon KA,Yang XD,Weiner LM,et al.Preclinical and clinical evaluations of ABX-EGF,a fully human anti-epidermal growth factor receptor antibody[J].Int J Radiat Oncol Biol Phys,2004,58:984.
  • 5[7]Daneshmand M,Parolin DA,Hirte HW,et al.A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients[J].Clin Cancer Res,2003,9:2457.
  • 6[8]Baselga J,Rischin D,Ranson M,et al.Phase Ⅰ safety pharmacokinetic and pharmacodynamic trial of ZD1839,a selective oral epidermal growth factor receptor tyrosine kinase inhibitor,in patients with five selected solid tumor types[J].J Clin Oncol,2002,20:4292.
  • 7[9]Goss G,Stewart D,Hirte H,et al.Initial results of part 2 of a phase Ⅰ/Ⅱ pharmacokinetics (PK),pharmacodynamic (PD) and biological activity study of ZD1839 (Iressa):NCIC CTG IND.122[J].Proc Am Soc Clin Oncol,2002,21:16.
  • 8[10]Fisher GA,Kuo T,Cho CD,et al.A phase Ⅱ study of gefitinib in combination with FOLFOX-4 (IFOX) in patients with metastatic colorectal cancer[J].J Clin Oncol,2004,22:3514.
  • 9[11]Townsley C,Major P,Siu LL,et al.Phase Ⅱ study of OSI-774 in patients with metastatic colorectal cancer[J].Gastrointest World Symp,2004:abstract 222.
  • 10[12]Meyerhardt JA,Xhu A,Enzinger PC,et al.Phase Ⅱ study of capecitabine,oxaliplatin and erlotinib in previously treated patients with metastatic colorectal cancer (MCRC)[J].J Clin Oncol,2004,22:3580.

二级参考文献22

  • 1Jose B. Why the epidermal growth factor receptor? The rational for cancer therapy. Oncologist,2002, (7 Suppl 4) :2-8.
  • 2Caponigro F,Basile M,de Rosa V,et al. New drugs in cancer therapy,National Tumor Institute, Naples, 17-18 June 2004. Anticancer Drugs,2005,16(2) :211-221.
  • 3Safavy A, Bonner JA, Waksal HW, et al. Synthesis and biological evaluation of paclitaxel-C225 conjugate as a model for targeted drug delivery.Bioconjug Chem,2003,14(2) :302-310.
  • 4Govindan R. Cetuximab in advanced non-small cell lung cancer. Clin Cancer Res,2004,10( 12 Pt 2) :4241S-4244S.
  • 5Prewett MC,Hooper AT, Bassi R,et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with ifinotecan against with human colorectal lumor xenografts. Clin Cancer Res,2002,8 ( 5 ) :994-1003.
  • 6Herbst RS, Shin DM. Monoclonal antibody to larger epidermal growth factor receptor positive tumors. Cancer,2002,94 ( 5 ) : 1593-1611.
  • 7Janmaat ML,Giaccone G. The epidermal growth factor receptor pathway and its inhibition as amicancer therapy. Drugs Today (Bare) ,2003,39Suppl C :61-80.
  • 8Meenakshi A,Ganesh V, Suresh R, et al. Radioimmuno targetting(99m) technetium labeled anti-epidermal growth factor receptor monoclonal antibodies in experimental tumor models. Q J Nucl Med,2003,47(2) :139-144.
  • 9Johns TF,Stockert E, Ritter G, et al. Novel monnelonal antibody specific for the de2-Tepidermal growth factor receptor thay also recognizes the EGFR expressed in cells containing ampllfication of the EGFR gene. Int Cancer, 2002,98 ( 3 ) :398-408.
  • 10Yang W, Barth RF, Ciesielski M J, et al. Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4. Clin Cancer Res,2005,11 ( 1 ) :341-350.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部